You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErgoloid mesylate
Accession NumberDB01049  (APRD00711, DB01287)
TypeSmall Molecule
GroupsApproved
DescriptionErgoloid mesylate is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Ergoloid Mesylate is the only vasodilator that has shown mild benefits in the treatment of vascular dementia. Ergoloid Mesylate is a mixture of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. It has been proposed to be a neuroprotective agent. The mechanism of its therapeutic actions is not clear.
Structure
Thumb
Synonyms
co-dergocrine mesilate
co-dergocrine mesylate
co-dergocrine methanesulfonate
codergocrine mesilate
codergocrine mesylate
codergocrine methanesulfonate
Dihydroergotoxine Mesilate
Dihydroergotoxine Mesylate
dihydroergotoxine methanesulfonate
Dihydroergotoxine Methanesulfonate
dihydroergotoxine methanesulfonates
dihydroergotoxine monomethanesulfonate
dihydrogenated ergot alkaloids
Ergoloid Mesylates
ergoloid methanesulfonate
ergoloid methanesulfonates
hydrogenated ergot alkaloids
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydergine Tablets, 1mgTablet1 mgOralSterimax Inc1968-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlkergotNot Available
GerimalNot Available
HydergineNot Available
Hydergine LCNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIX3S33EX3KW
CAS number8067-24-1
WeightAverage: 631.74
Monoisotopic: 631.267584003
Chemical FormulaC30H41N5O8S
InChI KeyFQHMMOGHDWAXDI-WUQHHHCFSA-N
InChI
InChI=1S/C29H37N5O5.CH4O3S/c1-15(2)28(27(37)34-16(3)26(36)33-10-6-9-23(33)29(34,38)39-28)31-25(35)18-11-20-19-7-5-8-21-24(19)17(13-30-21)12-22(20)32(4)14-18;1-5(2,3)4/h5,7-8,13,15-16,18,20,22-23,30,38H,6,9-12,14H2,1-4H3,(H,31,35);1H3,(H,2,3,4)/t16-,18+,20+,22+,23-,28+,29-;/m0./s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-methyl-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; methanesulfonic acid
SMILES
CS(O)(=O)=O.[H][C@@]12CCCN1C(=O)[[email protected]](C)N1C(=O)[C@](NC(=O)[[email protected]]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C
Pharmacology
IndicationFor use as an adjunct therapy for patients with dementia.
Structured Indications
PharmacodynamicsErgoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Mechanism of actionErgoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2 adrenergic receptorProtein groupyes
antagonist
Humannot applicabledetails
Alpha-1 adrenergic receptorProtein groupyes
antagonist
Humannot applicabledetails
Solute carrier organic anion transporter family member 2B1Proteinyes
inhibitor
HumanO94956 details
Serotonin ReceptorsProtein groupunknown
antagonist
Humannot applicabledetails
D(1A) dopamine receptorProteinunknown
antagonist
agonist
HumanP21728 details
D(2) dopamine receptorProteinunknown
antagonist
agonist
HumanP14416 details
GABA-A receptor (anion channel)Protein groupunknown
agonist
Humannot applicabledetails
Related Articles
AbsorptionRapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Volume of distributionNot Available
Protein binding98-99%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life3.5 hours
ClearanceNot Available
ToxicitySymptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Ergoloid mesylate can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Ergoloid mesylate can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Ergoloid mesylate can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AcebutololAcebutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acetophenazine.Approved
AdrafinilErgoloid mesylate may increase the hypertensive activities of Adrafinil.Withdrawn
AlmotriptanErgoloid mesylate may increase the vasoconstricting activities of Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprenololAlprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Withdrawn
AmiodaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.Approved, Investigational
AmitrazErgoloid mesylate may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergoloid mesylate.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergoloid mesylate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Amprenavir.Approved
AnisodamineErgoloid mesylate may increase the hypertensive activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Antithrombin III human.Approved
Aop200704Aop200704 may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
ApixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Apixaban.Approved
ApomorphineErgoloid mesylate may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineErgoloid mesylate may increase the hypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineErgoloid mesylate may increase the hypertensive activities of Arbutamine.Approved
ArformoterolErgoloid mesylate may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
AsenapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
AtomoxetineThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Azaperone.Vet Approved
BatimastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Batimastat.Experimental
BefunololErgoloid mesylate may increase the hypertensive activities of Befunolol.Experimental
BenazeprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benzamidine.Experimental
BetaxololBetaxolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BevantololBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BexaroteneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Ergoloid mesylate can be increased when it is combined with Bi201335.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bifeprunox.Investigational
BisoprololBisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BitolterolErgoloid mesylate may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Boceprevir.Approved
BopindololBopindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BortezomibThe metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brexpiprazole.Approved
BrimonidineErgoloid mesylate may increase the hypertensive activities of Brimonidine.Approved
BromocriptineErgoloid mesylate may increase the vasoconstricting activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bromperidol.Investigational
BucindololBucindolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
BufuralolBufuralol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental, Investigational
BupranololBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.Approved, Investigational
CabergolineErgoloid mesylate may increase the vasoconstricting activities of Cabergoline.Approved
CandoxatrilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Carbomycin.Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cariprazine.Approved
CarteololCarteolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
CarvedilolCarvedilol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
CeliprololCeliprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
CeritinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ceritinib.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorprothixene.Approved, Withdrawn
ChymostatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.Approved
CirazolineErgoloid mesylate may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergoloid mesylate.Approved
ClarithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ergoloid mesylate can be decreased when combined with Clemastine.Approved
ClenbuterolErgoloid mesylate may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomipramine.Approved, Vet Approved
ClonidineErgoloid mesylate may increase the hypertensive activities of Clonidine.Approved
ClotrimazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clozapine.Approved
CobicistatThe metabolism of Ergoloid mesylate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.Approved
CyclosporineThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergoloid mesylate.Investigational
DarunavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ergoloid mesylate can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desipramine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.Approved
DetomidineErgoloid mesylate may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineErgoloid mesylate may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergoloid mesylate.Approved
DihydroergotamineErgoloid mesylate may increase the vasoconstricting activities of Dihydroergotamine.Approved
DiltiazemThe metabolism of Ergoloid mesylate can be decreased when combined with Diltiazem.Approved
DipivefrinErgoloid mesylate may increase the hypertensive activities of Dipivefrin.Approved
DobutamineErgoloid mesylate may increase the hypertensive activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Ergoloid mesylate.Approved
DoxepinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Doxepin.Approved
DoxycyclineThe metabolism of Ergoloid mesylate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.Approved, Vet Approved
DroxidopaErgoloid mesylate may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergoloid mesylate.Approved
EcabetThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ecabet.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Elafin.Investigational
EletriptanErgoloid mesylate may increase the vasoconstricting activities of Eletriptan.Approved, Investigational
EnalaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.Approved
EphedrineErgoloid mesylate may increase the hypertensive activities of Ephedrine.Approved
EpinephrineErgoloid mesylate may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ergonovine.Approved
ErgotamineErgoloid mesylate may increase the vasoconstricting activities of Ergotamine.Approved
ErythromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
EtilefrineErgoloid mesylate may increase the hypertensive activities of Etilefrine.Withdrawn
EtravirineThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Etravirine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolErgoloid mesylate may increase the hypertensive activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.Approved, Illicit, Investigational, Vet Approved
FluconazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Fluconazole.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergoloid mesylate.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergoloid mesylate.Approved, Investigational
FormoterolErgoloid mesylate may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Fosphenytoin.Approved
FrovatriptanErgoloid mesylate may increase the vasoconstricting activities of Frovatriptan.Approved, Investigational
Fusidic AcidThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Geldanamycin.Experimental
GM6001The serum concentration of Ergoloid mesylate can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
GuanabenzErgoloid mesylate may increase the hypertensive activities of Guanabenz.Approved
GuanfacineErgoloid mesylate may increase the hypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.Approved
HexoprenalineErgoloid mesylate may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineErgoloid mesylate may increase the hypertensive activities of Higenamine.Investigational
HirulogThe serum concentration of Ergoloid mesylate can be increased when it is combined with Hirulog.Experimental
IdelalisibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Ergoloid mesylate can be increased when it is combined with idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.Approved
ImatinibThe metabolism of Ergoloid mesylate can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergoloid mesylate.Approved
IndenololIndenolol may increase the vasoconstricting activities of Ergoloid mesylate.Withdrawn
IndinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Ergoloid mesylate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.Approved
IsoetarineErgoloid mesylate may increase the hypertensive activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoprenalineErgoloid mesylate may increase the hypertensive activities of Isoprenaline.Approved
IsoxsuprineErgoloid mesylate may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Josamycin.Approved
KetoconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
LepirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.Approved
LevobunololLevobunolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.Approved
LinagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergoloid mesylate.Approved, Investigational
LisinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideErgoloid mesylate may increase the vasoconstricting activities of Lisuride.Approved
LithiumThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.Approved
LofexidineErgoloid mesylate may increase the hypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergoloid mesylate.Approved
LovastatinThe metabolism of Ergoloid mesylate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.Approved
Lu AA21004Ergoloid mesylate may increase the vasoconstricting activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ergoloid mesylate can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.Approved
MedetomidineErgoloid mesylate may increase the hypertensive activities of Medetomidine.Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Melperone.Approved
MephentermineErgoloid mesylate may increase the hypertensive activities of Mephentermine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.Approved
MetaraminolErgoloid mesylate may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methotrimeprazine.Approved
MethoxamineErgoloid mesylate may increase the hypertensive activities of Methoxamine.Approved
MethyldopaErgoloid mesylate may increase the hypertensive activities of Methyldopa.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
MidodrineErgoloid mesylate may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Ergoloid mesylate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Milnacipran.Approved
MirabegronErgoloid mesylate may increase the hypertensive activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergoloid mesylate.Approved
MitotaneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moclobemide.Approved
ModafinilThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Molindone.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergoloid mesylate can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
NafamostatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Nafcillin.Approved
NaphazolineErgoloid mesylate may increase the hypertensive activities of Naphazoline.Approved
NaratriptanErgoloid mesylate may increase the vasoconstricting activities of Naratriptan.Approved, Investigational
NCX 4016The serum concentration of Ergoloid mesylate can be increased when it is combined with NCX 4016.Investigational
NebivololErgoloid mesylate may increase the hypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Ergoloid mesylate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ergoloid mesylate can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinErgoloid mesylate may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NorepinephrineErgoloid mesylate may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergoloid mesylate.Approved
NylidrinErgoloid mesylate may increase the hypertensive activities of Nylidrin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Ergoloid mesylate can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Oleandomycin.Vet Approved
OlodaterolErgoloid mesylate may increase the hypertensive activities of Olodaterol.Approved
OmapatrilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Ergoloid mesylate.Approved
OrciprenalineErgoloid mesylate may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Otamixaban.Investigational
OxprenololOxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
OxymetazolineErgoloid mesylate may increase the hypertensive activities of Oxymetazoline.Approved
PalbociclibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergoloid mesylate.Approved, Investigational
PenbutololPenbutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
PentobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perazine.Investigational
PergolideErgoloid mesylate may increase the vasoconstricting activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergoloid mesylate.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergoloid mesylate.Approved
PhenobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.Approved
PhenylephrineErgoloid mesylate may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineErgoloid mesylate may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Ergoloid mesylate can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pimozide.Approved
PindololPindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipotiazine.Approved
PirbuterolErgoloid mesylate may increase the hypertensive activities of Pirbuterol.Approved
PosaconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
PrimidoneThe metabolism of Ergoloid mesylate can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine.Approved
ProcaterolErgoloid mesylate may increase the hypertensive activities of Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promethazine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Propericiazine.Approved
PropranololPropranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.Approved
PRX-00023Ergoloid mesylate may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineErgoloid mesylate may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.Approved, Investigational
RacecadotrilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Racecadotril.Investigational
RacepinephrineErgoloid mesylate may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Raclopride.Investigational
RactopamineErgoloid mesylate may increase the hypertensive activities of Ractopamine.Vet Approved
RamiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Ergoloid mesylate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.Approved
RemikirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.Approved
RifabutinThe metabolism of Ergoloid mesylate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ergoloid mesylate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ergoloid mesylate can be increased when combined with Rifapentine.Approved
RilmenidineErgoloid mesylate may increase the hypertensive activities of Rilmenidine.Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ritanserin.Investigational
RitobegronErgoloid mesylate may increase the hypertensive activities of Ritobegron.Investigational
RitodrineErgoloid mesylate may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Rivaroxaban.Approved
RizatriptanErgoloid mesylate may increase the vasoconstricting activities of Rizatriptan.Approved
RomifidineErgoloid mesylate may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleErgoloid mesylate may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RoxithromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Roxithromycin.Approved, Withdrawn
SalbutamolErgoloid mesylate may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
SalmeterolErgoloid mesylate may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergoloid mesylate.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertraline.Approved
SildenafilThe metabolism of Ergoloid mesylate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Sitagliptin.Approved, Investigational
SolabegronErgoloid mesylate may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Solithromycin.Investigational
SotalolSotalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
SpiraprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Spirapril.Approved
SR 58611Ergoloid mesylate may increase the hypertensive activities of SR 58611.Investigational
St. John's WortThe serum concentration of Ergoloid mesylate can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ergoloid mesylate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.Approved
SumatriptanErgoloid mesylate may increase the vasoconstricting activities of Sumatriptan.Approved, Investigational
SynephrineErgoloid mesylate may increase the hypertensive activities of Synephrine.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergoloid mesylate.Approved
TelaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Temocapril.Experimental, Investigational
TerbutalineErgoloid mesylate may increase the hypertensive activities of Terbutaline.Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.Approved
ThiorphanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tiapride.Investigational
TiclopidineThe metabolism of Ergoloid mesylate can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
TipranavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineErgoloid mesylate may increase the hypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergoloid mesylate.Approved, Investigational
TrandolaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.Approved, Investigational
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergoloid mesylate.Approved
TroleandomycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Ergoloid mesylate.Investigational
TulobuterolErgoloid mesylate may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ulinastatin.Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergoloid mesylate.Approved
VerapamilThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.Approved
VilazodoneErgoloid mesylate may increase the vasoconstricting activities of Vilazodone.Approved
VildagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineErgoloid mesylate may increase the vasoconstricting activities of Vortioxetine.Approved
XimelagatranThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineErgoloid mesylate may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Ergoloid mesylate may increase the hypertensive activities of YM-178.Investigational
Ym150The serum concentration of Ergoloid mesylate can be increased when it is combined with Ym150.Investigational
ZiprasidoneThe metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.Approved
ZolmitriptanErgoloid mesylate may increase the vasoconstricting activities of Zolmitriptan.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC04AE51C04AE01
AHFS Codes
  • 12:16.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8284
Blood Brain Barrier-0.9494
Caco-2 permeable-0.6447
P-glycoprotein substrateSubstrate0.6838
P-glycoprotein inhibitor IInhibitor0.6581
P-glycoprotein inhibitor IINon-inhibitor0.8001
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.75
CYP450 2D6 substrateNon-substrate0.7966
CYP450 3A4 substrateSubstrate0.6681
CYP450 1A2 substrateNon-inhibitor0.7702
CYP450 2C9 inhibitorNon-inhibitor0.7072
CYP450 2D6 inhibitorNon-inhibitor0.9221
CYP450 2C19 inhibitorNon-inhibitor0.6493
CYP450 3A4 inhibitorNon-inhibitor0.7973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8464
Ames testNon AMES toxic0.6324
CarcinogenicityNon-carcinogens0.6535
BiodegradationNot ready biodegradable0.9321
Rat acute toxicity2.5438 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8821
hERG inhibition (predictor II)Inhibitor0.5783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg
Prices
Unit descriptionCostUnit
Ergoloid mesylates powder87.5USD g
Ergoloid mesylates 1 mg tablet1.3USD tablet
Hydergine 1 mg Tablet1.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.8Not Available
Predicted Properties
PropertyValueSource
logP2.17ChemAxon
pKa (Strongest Acidic)9.71ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity143.66 m3·mol-1ChemAxon
Polarizability57.99 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentErgopeptines
Alternative Parents
Substituents
  • Hybrid peptide
  • Ergopeptine
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • N-acyl-alpha amino acid or derivatives
  • Quinoline
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 3-piperidinecarboxamide
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • N-alkylpiperazine
  • Benzenoid
  • Piperidine
  • Piperazine
  • Oxazolidinone
  • 1,4-diazinane
  • Heteroaromatic compound
  • Alkanesulfonic acid
  • Tertiary carboxylic acid amide
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonic acid
  • Pyrrolidine
  • Pyrrole
  • Methanesulfonate
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Orthocarboxylic acid derivative
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Lu WJ, Huang JD, Lai ML: The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol. 2006 Jun;46(6):628-34. [PubMed:16707409 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 1AP08908 Details
5-hydroxytryptamine receptor 1BP28222 Details
5-hydroxytryptamine receptor 1DP28221 Details
5-hydroxytryptamine receptor 1EP28566 Details
5-hydroxytryptamine receptor 1FP30939 Details
5-hydroxytryptamine receptor 2AP28223 Details
5-hydroxytryptamine receptor 2BP41595 Details
5-hydroxytryptamine receptor 2CP28335 Details
5-hydroxytryptamine receptor 3AP46098 Details
5-hydroxytryptamine receptor 3BO95264 Details
5-hydroxytryptamine receptor 3CQ8WXA8 Details
5-hydroxytryptamine receptor 3DQ70Z44 Details
5-hydroxytryptamine receptor 3EA5X5Y0 Details
5-hydroxytryptamine receptor 4Q13639 Details
5-hydroxytryptamine receptor 6P50406 Details
5-hydroxytryptamine receptor 7P34969 Details
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415 ]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351 ]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415 ]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351 ]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Tvrdeic A, Pericic D: Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors. Coll Antropol. 2003;27 Suppl 1:175-82. [PubMed:12955907 ]
  2. Tvrdeic A, Pericic D: Dihydrogenated ergot compounds bind with high affinity to GABAA receptor-associated Cl- ionophore. Eur J Pharmacol. 1991 Sep 4;202(1):109-11. [PubMed:1664802 ]
  3. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Althaus M, Retzow A, Castell JV, Gomez-Lechon MJ, Amalou Z, Rose T, Appel K: In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine. Xenobiotica. 2000 Nov;30(11):1033-45. [PubMed:11197065 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23